Rapamycin (Sirolimus) vs NMN/NR: Head-to-Head Efficacy for Longevity

Why These Two Compounds Are Compared

Rapamycin and NMN/NR sit at opposite ends of the longevity pharmacology spectrum, yet both appear in the same patient conversations because they target two of the best-studied hallmarks of aging. Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a nutrient-sensing kinase that regulates cell growth, autophagy, and senescence [1]. NMN and NR are precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme that declines with age and supports mitochondrial function, DNA repair, and sirtuin activity [2].

The comparison is not straightforward. Rapamycin is an FDA-approved prescription immunosuppressant with decades of pharmacokinetic data. NMN and NR are sold over the counter (though the FDA challenged NMN's supplement status in late 2022, a decision that remains partially unresolved). Their evidence bases differ in depth, rigor, and endpoint relevance. A head-to-head randomized controlled trial comparing the two has never been conducted, so any efficacy comparison must synthesize data across separate studies with different populations, doses, and outcome measures [3].

Mechanism of Action: mTOR Inhibition vs NAD+ Repletion

Rapamycin binds FKBP12 and inhibits mTOR complex 1 (mTORC1), suppressing protein synthesis and activating autophagy, the cellular recycling process that clears damaged organelles and misfolded proteins. At low, intermittent doses used in longevity protocols, rapamycin preferentially inhibits mTORC1 while sparing mTORC2, the complex linked to insulin signaling disruption and immunosuppression [1]. This selectivity is dose- and schedule-dependent. Weekly pulsed dosing (3 to 6 mg) allows mTORC2 to recover between doses, a protocol the NIA Interventions Testing Program (ITP) has validated in mice.

NMN and NR take a different route. Both are converted enzymatically to NAD+ through the salvage pathway. NMN is phosphorylated by nicotinamide phosphoribosyltransferase (NAMPT), while NR is first phosphorylated by nicotinamide riboside kinases (NRK1/2) [2]. The downstream NAD+ activates sirtuins (SIRT1 through SIRT7), poly(ADP-ribose) polymerases involved in DNA repair, and CD38/CD157 ectoenzymes. Blood NAD+ levels drop roughly 50% between ages 40 and 60 in some cohorts, which provides the rationale for supplementation [4].

These pathways intersect. mTOR and AMPK/sirtuin signaling are reciprocally regulated: when mTOR is active, AMPK and SIRT1 are suppressed, and vice versa. In theory, rapamycin (mTOR suppression) and NMN/NR (sirtuin activation) could be complementary. No clinical trial has tested this hypothesis directly.

Preclinical Lifespan Evidence

Rapamycin is the single most reproducible pharmacological lifespan intervention in mammals. The ITP, a multi-site NIA-funded program, first showed in 2009 that rapamycin extended median lifespan by 9% in male and 14% in female genetically heterogeneous mice, even when started at 600 days of age (roughly equivalent to a 60-year-old human) [5]. Subsequent ITP studies using higher doses (42 ppm in chow) reported median lifespan extensions of up to 23% in males and 26% in females [6]. These results have been replicated across three independent laboratories within the ITP and by outside groups.

NMN and NR have not demonstrated lifespan extension in published mammalian studies. NMN improved glucose tolerance, lipid profiles, and physical activity in aging mice (Mills et al., Cell Metabolism 2016), but the study did not measure maximum lifespan [7]. NR extended lifespan in a mouse model of ataxia-telangiectasia (Fang et al., Cell Metabolism 2016) but not in wild-type animals. A 2024 preprint from the ITP reported that NR did not significantly extend lifespan in genetically heterogeneous mice at two dose levels [8].

This gap matters. Lifespan extension is the gold-standard endpoint in preclinical geroscience. Rapamycin clears that bar repeatedly. NMN and NR improve healthspan markers (metabolic function, exercise capacity, tissue NAD+ levels) but have not crossed the lifespan threshold in normal aging mice.

Human Clinical Trial Data

Rapamycin: The PEARL Trial and Immune Aging Studies

The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, enrolled healthy adults aged 50 to 85 taking low-dose rapamycin (typically 5 to 6 mg once weekly). Participants reported improved subjective health outcomes, and a subset showed favorable changes in immune biomarkers. The study design was observational/participatory rather than a double-blind placebo-controlled RCT, which limits causal claims, but it represents the largest human rapamycin-for-aging dataset to date [3].

Earlier work by Mannick et al. (2014) used everolimus (an mTOR inhibitor closely related to rapamycin) in adults aged 65 and older and found that 6 weeks of low-dose mTOR inhibition improved influenza vaccine response by approximately 20%, a marker of immune rejuvenation [9]. Dr. Joan Mannick noted at the time: "This is the first study to demonstrate that an aging pathway can be targeted to improve immune function in the elderly." A follow-up trial (Mannick et al., Science Translational Medicine 2018) confirmed this finding with a different mTOR inhibitor combination [10].

NMN: Yoshino et al. and Metabolic Endpoints

The strongest human NMN data comes from Yoshino et al. (Science, 2021), a double-blind, placebo-controlled RCT in 25 postmenopausal, prediabetic women. Participants received 250 mg/day of NMN for 10 weeks. The NMN group showed a 25% increase in muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp (the gold-standard technique), along with improved muscle remodeling gene expression [11]. The study did not measure aging biomarkers, immune function, or any longevity-specific endpoint.

For NR, the most cited human trial is Martens et al. (2018), which gave 1 to 000 mg/day of NR (as NIAGEN) to 24 healthy older adults for 6 weeks. NR reduced aortic stiffness (measured by carotid-femoral pulse wave velocity) and trended toward lower systolic blood pressure, particularly in those with Stage 1 hypertension at baseline [12]. A larger NR trial (Elhassan et al., Cell Reports 2019) confirmed that oral NR raises skeletal muscle NAD+ metabolites in older men but did not report functional improvements [13].

Dr. Charles Brenner, who discovered the NR kinase pathway, stated in a 2020 commentary: "NAD+ precursors are not anti-aging drugs in the way the public understands the term. They are metabolic support compounds that correct a specific deficit" [14].

Comparing the Evidence: A Framework

Three dimensions separate these compounds when evaluating efficacy for longevity.

Strength of lifespan evidence. Rapamycin scores highest of any drug tested in the ITP. It extended lifespan across sexes, genetic backgrounds, ages at initiation, and independent laboratories [5][6]. NMN and NR have zero positive mammalian lifespan results in wild-type models. This is the single largest differentiator.

Human metabolic and functional data. NMN and NR have more controlled human metabolic data. The Yoshino trial [11] used the gold-standard insulin sensitivity measurement. The Martens trial [12] measured arterial stiffness, a validated cardiovascular aging marker. Rapamycin human data is either observational (PEARL [3]) or involves the analog everolimus (Mannick [9][10]). Neither compound has completed a large, long-duration human RCT with a primary aging endpoint.

Regulatory and safety profile. Rapamycin carries known risks: mouth sores (stomatitis), impaired wound healing, dyslipidemia, and (at immunosuppressive doses) infection susceptibility. Pulsed low-dose protocols appear better tolerated, but long-term safety data for the off-label longevity indication does not exist [3]. NMN and NR have clean short-term safety profiles in trials lasting 6 to 12 weeks. Oral NR at 1 to 000 mg/day and NMN at 250 mg/day raised no significant adverse events [11][12]. Long-term data (>1 year) is absent for both.

Dosing Protocols in Longevity Practice

Off-label rapamycin for longevity typically follows a pulsed weekly schedule. Common protocols range from 3 mg to 6 mg once per week, sometimes with a 2-week-on, 1-week-off cycle. Some clinicians check sirolimus trough levels 5 to 7 days post-dose, targeting a trough below 5 ng/mL. The Endocrine Society has not issued guidelines for rapamycin in aging, and no FDA-approved longevity indication exists [1].

NMN is dosed at 250 to 1 to 000 mg daily, typically taken in the morning. NR (as NIAGEN or TRU NIAGEN) is commonly dosed at 300 to 1 to 000 mg daily. Both are taken orally. Neither has a defined therapeutic window for longevity endpoints. The FDA's 2022 determination that NMN had been studied as a drug (by Metro International Biotech) before being marketed as a supplement created regulatory ambiguity that persists in 2026 [15].

Side Effects and Monitoring

Rapamycin side effects at immunosuppressive doses (2 to 5 mg daily, as used in transplant medicine) include aphthous ulcers, hyperlipidemia, thrombocytopenia, impaired glucose tolerance, and increased infection risk. At pulsed longevity doses (5 mg weekly), the PEARL cohort reported mouth sores as the most common adverse event, occurring in roughly 15 to 20% of participants and typically resolving with dose reduction [3]. Clinicians monitoring rapamycin for longevity generally order CBC, metabolic panel, lipid panel, and sirolimus trough levels every 3 to 6 months [9].

NMN and NR carry minimal reported side effects. The most common complaints are mild GI symptoms (nausea, bloating) at higher doses. A theoretical concern exists that chronic NAD+ elevation could fuel growth of occult cancers by supporting DNA repair and cellular proliferation in malignant cells, though no clinical evidence supports this [14]. Some researchers also raise the possibility that chronic NR/NMN supplementation could downregulate endogenous NAMPT expression, but this has not been confirmed in human studies.

Can You Combine Rapamycin and NMN/NR?

No published trial has tested the combination. The mechanistic rationale is plausible: rapamycin suppresses mTORC1 and activates autophagy, while NMN/NR supports NAD+-dependent sirtuin activity and mitochondrial function. These pathways are distinct and, in preclinical models, synergistic with caloric restriction. Some longevity clinicians prescribe both concurrently (rapamycin weekly, NMN or NR daily), but this practice is based on mechanistic inference, not outcome data.

The risk of interaction is low from a pharmacokinetic standpoint. Rapamycin is metabolized by CYP3A4 and P-glycoprotein. NMN and NR are not known CYP3A4 inhibitors or inducers. Drug-drug interactions are unlikely, though formal interaction studies have not been performed [1][11].

Who Might Benefit From Each Compound

Patient selection differs based on evidence quality and risk tolerance. Rapamycin may be most appropriate for individuals with elevated mTOR signaling markers, a family history of cancer (mTOR inhibition has anti-tumor properties), or those who prioritize the strongest available preclinical lifespan data and accept prescription drug monitoring requirements [5][6]. A physician must prescribe and monitor rapamycin, and patients need regular blood work.

NMN or NR may suit individuals seeking a lower-barrier intervention with demonstrated NAD+ repletion and metabolic benefits. The Yoshino data [11] is particularly relevant for postmenopausal women with insulin resistance. NR's arterial stiffness data [12] applies to older adults with early cardiovascular aging. Neither requires a prescription (though NMN's regulatory status remains uncertain), and both have favorable short-term safety data.

Age and metabolic status also factor in. NAD+ decline accelerates after age 40, which is when the theoretical benefit of precursor supplementation becomes most relevant [4]. Rapamycin's lifespan extension in mice was significant even when started late in life (equivalent to age 60 in humans), suggesting a wider window of potential benefit [5].

Cost and Access

Rapamycin (generic sirolimus) costs approximately $30 to $80 per month at longevity doses (5 mg weekly) through compounding pharmacies or generic tablets, but requires a prescription, an initial consultation, and ongoing lab monitoring that adds $200 to $500 per year. Insurance does not cover off-label longevity use.

NMN costs $40 to $120 per month depending on dose and brand. NR (as TRU NIAGEN) runs roughly $40 to $50 per month at 300 mg/day. Neither requires a prescription or lab monitoring, making the total cost of entry lower despite similar supplement prices. Quality control varies substantially across NMN brands because the supplement lacks USP monograph standardization.